Neuropathic Pain in Patients with Psoriatic Arthritis: A Bystander or a Gamechanger?

Mehmet Serkan Kılıçoğlu; Mert Kara; Ozan Volkan Yurdakul

Makale detayları

Neuropathic Pain in Patients with Psoriatic Arthritis: A Bystander or a Gamechanger?

Yazarlar:

Mehmet Serkan Kılıçoğlu | Mert Kara | Ozan Volkan Yurdakul

Yayıncı:

Sakarya University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Sakarya Tıp Dergisi Vol.13 Issue 3, pp.412-420

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001298968

pISSN:

2146-409X

Anahtar kelimeler:

Özet:

 Objectives The relationship between clinical and laboratory parameters associated with the neuropathic pain presence in Psoriatic Arthritis is not well known and has not been adequately studied. Based on these assumptions, the aim of our study is to investigate how often neuropathic pain occurs in Psoriatic Arthritis patients and how much it is related to the clinical and laboratory parameters of the disease. Methods In the cross-sectional study, 45 Psoriatic Arthritis patients diagnosed according to The Classification Criteria for Psoriatics were included. In our study, Pain Detect Questionnaire PDQ was used to assess the neuropathic pain characteristics. Presence of enthesitis was determined by SPARCC to ensure objective measurements. Functional status was evaluated with the Health Assessment Questionnaire HAQ. The Short Form-36 SF-36 questionnaire was used to evaluate the quality of life. Results A total of 45 patients were included in the study. The mean duration of symptoms was 78.91  95.8 months. There are 16 patients receiving Nsaid treatment, 28 patients receiving DMARD treatment, and 13 patients receiving biological therapy. Among the patients included in the study, 30 patients with neuropathic pain and 15 without neuropathic pain were found according to the Pain Detect questionnaire. A significant difference was observed between these two groups in the results of DAPSA, VAS movement, HAQ, morning stiffness, and SF-36 Body pain. Conclusion Our study has shown that neuropathic pain has a high prevalence in Psoriatic Arthritis patients. This association was observed to be related to functional limitation. Additionally, the DAPSA score was found to be significantly higher in patients with neuropathic pain due to pain sensation which suggests that it may be a factor reducing treatment success. It is conceivable that the recognition and treatment of neuropathic pain may increase the success of Psoriatic Arthritis treatment.

 Objectives The relationship between clinical and laboratory parameters associated with the neuropathic pain presence in Psoriatic Arthritis is not well known and has not been adequately studied. Based on these assumptions, the aim of our study is to investigate how often neuropathic pain occurs in Psoriatic Arthritis patients and how much it is related to the clinical and laboratory parameters of the disease. Methods In the cross-sectional study, 45 Psoriatic Arthritis patients diagnosed according to The Classification Criteria for Psoriatics were included. In our study, Pain Detect Questionnaire PDQ was used to assess the neuropathic pain characteristics. Presence of enthesitis was determined by SPARCC to ensure objective measurements. Functional status was evaluated with the Health Assessment Questionnaire HAQ. The Short Form-36 SF-36 questionnaire was used to evaluate the quality of life. Results A total of 45 patients were included in the study. The mean duration of symptoms was 78.91  95.8 months. There are 16 patients receiving Nsaid treatment, 28 patients receiving DMARD treatment, and 13 patients receiving biological therapy. Among the patients included in the study, 30 patients with neuropathic pain and 15 without neuropathic pain were found according to the Pain Detect questionnaire. A significant difference was observed between these two groups in the results of DAPSA, VAS movement, HAQ, morning stiffness, and SF-36 Body pain. Conclusion Our study has shown that neuropathic pain has a high prevalence in Psoriatic Arthritis patients. This association was observed to be related to functional limitation. Additionally, the DAPSA score was found to be significantly higher in patients with neuropathic pain due to pain sensation which suggests that it may be a factor reducing treatment success. It is conceivable that the recognition and treatment of neuropathic pain may increase the success of Psoriatic Arthritis treatment.

 Objectives The relationship between clinical and laboratory parameters associated with the neuropathic pain presence in Psoriatic Arthritis is not well known and has not been adequately studied. Based on these assumptions, the aim of our study is to investigate how often neuropathic pain occurs in Psoriatic Arthritis patients and how much it is related to the clinical and laboratory parameters of the disease. Methods In the cross-sectional study, 45 Psoriatic Arthritis patients diagnosed according to The Classification Criteria for Psoriatics were included. In our study, Pain Detect Questionnaire PDQ was used to assess the neuropathic pain characteristics. Presence of enthesitis was determined by SPARCC to ensure objective measurements. Functional status was evaluated with the Health Assessment Questionnaire HAQ. The Short Form-36 SF-36 questionnaire was used to evaluate the quality of life. Results A total of 45 patients were included in the study. The mean duration of symptoms was 78.91  95.8 months. There are 16 patients receiving Nsaid treatment, 28 patients receiving DMARD treatment, and 13 patients receiving biological therapy. Among the patients included in the study, 30 patients with neuropathic pain and 15 without neuropathic pain were found according to the Pain Detect questionnaire. A significant difference was observed between these two groups in the results of DAPSA, VAS movement, HAQ, morning stiffness, and SF-36 Body pain. Conclusion Our study has shown that neuropathic pain has a high prevalence in Psoriatic Arthritis patients. This association was observed to be related to functional limitation. Additionally, the DAPSA score was found to be significantly higher in patients with neuropathic pain due to pain sensation which suggests that it may be a factor reducing treatment success. It is conceivable that the recognition and treatment of neuropathic pain may increase the success of Psoriatic Arthritis treatment.

 AMAÇ Psoriatik Artritte nöropatik ağrı varlığı ile ilişkili klinik ve laboratuvar parametreleri arasındaki ilişki iyi bilinmemektedir ve yeterince çalışılmamıştır. Bu varsayımlara dayanarak çalışmamızın amacı, Psoriatik Artrit hastalığı bulunan kişilerde nöropatik ağrı dediğimiz durumun ne sıklıkta olduğunu ve hastalığın klinik ve laboratuvar parametreleri ile ne kadar ilişkili olduğunu araştırmaktır. MATERYAL VE METOD Kesitsel çalışmada The Classification Criteria for Psoriaticse göre tanı almış 45 Psöriatik Artrit hastası dahil edilmiştir. Çalışmamızda nöropatik ağrı özelliklerinin değerlendirilmesi için Pain Detect Anketi PDQ kullanıldı. Objektif ölçümler yapılması amacıyla SPARCC Spondyloarthritis Research Consortium of Canada aracılığıyla entezit varlığı belirlendi. Fonkiyonel durum, Sağlık Değerlendirme Anketi HAQ ile değerlendirilmiştir. Yaşam kalitesini değerlendirmek için Kısa Form-36 SF-36 anketi kullanılmıştır. BULGULAR Çalışmaya toplam 45 hasta 32 kadın 71,1, 13 erkek 28,9 alınmıştır. Ortalama semptom süresi 78,91  95,8 aydır. Nsaid tedavisi alan 16 hasta 35,6, DMARD tedavisi alan 28 hasta 62,2, Biyolojik tedavi alan 13 hasta 28,9 bulunmaktadır. Çalışmaya alınan hastalarda Pain Detect anketine göre NP olan 30 hasta 66,7, Nöropatik ağrı olmayan 15 33,3 saptanmıştır. Bu iki grup arasında DAPSA, VAS hareket, HAQ, sabah tutukluğu ve SF-36 Vücut ağrısı sonuçlarında anlamlı farklılık saptanmıştır. SONUÇ Psoriatik Artritli hastalarda Nöropatik ağrının yüksek prevelansta bulunduğu çalışmamızla gösterilmiştir. Bu birlikteliğin fonksiyonel kısıtlılıkla ilişkili olduğu görülmüştür. Ayrıca Ağrı hissi nedeniyle DAPSA skoru Nöropatik ağrı olan hastalarda anlamlı olarak yüksek bulunmuş ve bu da tedavi başarısını düşüren bir etken olabileceğini düşündürmektedir. Nöropatik ağrının tanınması ve tedavi edilmesinin Psoriatik Artrit tedavisindeki başarıyı arttırabileceği düşünülebilir.

Makale detayları

Neuropathic Pain in Patients with Psoriatic Arthritis: A Bystander or a Gamechanger?

Yazarlar:

Mehmet Serkan Kılıçoğlu | Mert Kara | Ozan Volkan Yurdakul

Yayıncı:

Sakarya University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Sakarya Tıp Dergisi Vol.13 Issue 3, pp.412-420

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001298968

pISSN:

2146-409X

Psoriatic Arthiritis

Neuropatic Pain

DMARD

Biological Treatment

Pain

RheumatologyPsoriatik Artrit

Nöropatik Ağrı

Romatoloji

Ağrı

Biyolojik Tedavi

DMARD

Sayı

Makale detayları

Yazarlar: Mehmet Serkan Kılıçoğlu | Mert Kara | Ozan Volkan Yurdakul

Yayıncı: Sakarya University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Sakarya Tıp Dergisi Vol.13 Issue 3, pp.412-420

Belge Tipi: Makale

Yayın Tarihi: 9/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001298968

pISSN: 2146-409X

Sayı

Yazarlar:

Mehmet Serkan Kılıçoğlu | Mert Kara | Ozan Volkan Yurdakul

Yayıncı:

Sakarya University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Sakarya Tıp Dergisi Vol.13 Issue 3, pp.412-420

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001298968

pISSN:

2146-409X